Teva and Alvotech Announce Strategic Partnership to Collaborate in the U.S. Biosimilar Market
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Teva Pharma (TEVA) PT Raised to $11 at Cowen
August 5, 2020 1:04 PM EDTCowen analyst Ken Cacciatore raised the price target on Teva Pharma (NYSE: TEVA) to $11.00 (from $9.00) while maintaining a Market Perform rating.
The analyst commented, "Teva is performing as well as can be expected, with good cost reductions while still executing on the Austedo... More
